Jonathan Ostrem, MD, PhD

Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
Address600 16th Street, #N212
San Francisco CA 94158
ORCID ORCID Icon0000-0001-9085-1615 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San Francisco, CAPhD09/2013Chemical Biology
    University of California, San Francisco, CAMD06/2016
    Brigham and Women's Hospital, Harvard Medical School, MA06/2018Internal Medicine
    Dana-Farber Cancer Institute, Harvard Medical School, MA06/2022Medical Oncology
    Collapse Awards and Honors
    Forbes Magazine2014Forbes 30 Under 30: Science & Healthcare
    University of California, San Diego2007Joseph E. Mayer Award
    University of California, San Diego2007Phi Beta Kappa
    University of California, San Diego2006Thomas E. Curtis Scholarship

    Collapse Overview 
    Collapse Overview
    Our laboratory uses chemical biology approaches to develop new modes of cancer therapy. We are interested in the design of small molecule and antibody-based cancer therapeutics directed at oncogenic signaling pathways. To accomplish this we use a variety of techniques, including synthetic organic chemistry, biochemistry, protein engineering, and cellular and mouse models of human cancer.
    Collapse Websites

    Collapse Research 
    Collapse Research Activities and Funding
    Enhancing the precision of targeted therapies for EGFR-mutant lung cancer
    Lung Cancer Research Foundation Dec 14, 2022 - Dec 13, 2024
    Role: Principal Investigator
    Description: Development of a new approach for tumor-specific release of EGFR inhibitors to maximize efficacy while limiting EGFR-related toxicities in patients.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Highly specific intracellular ubiquitination of a small molecule. bioRxiv. 2024 Jan 28. Li W, Garcia-Rivera EM, Mitchell DC, Chick JM, Maetani M, Knapp JM, Matthews GM, Shirasaki R, de Matos Simoes R, Viswanathan V, Pulice JL, Rees MG, Roth JA, Gygi SP, Mitsiades CS, Kadoch C, Schreiber SL, Ostrem JML. PMID: 38328167; PMCID: PMC10849632.
      View in: PubMed   Mentions:
    2. Rational Screening for Cooperativity in Small-Molecule Inducers of Protein-Protein Associations. J Am Chem Soc. 2023 10 25; 145(42):23281-23291. Liu S, Tong B, Mason JW, Ostrem JM, Tutter A, Hua BK, Tang SA, Bonazzi S, Briner K, Berst F, Zécri FJ, Schreiber SL. PMID: 37816014; PMCID: PMC10603787.
      View in: PubMed   Mentions: 2     Fields:    Translation:Cells
    3. Rational screening for cooperativity in small-molecule inducers of protein-protein associations. bioRxiv. 2023 May 24. Liu S, Tong B, Mason JW, Ostrem JM, Tutter A, Hua BK, Tang SA, Bonazzi S, Briner K, Berst F, Zécri FJ, Schreiber SL. PMID: 37292909; PMCID: PMC10245867.
      View in: PubMed   Mentions:
    4. Overcoming KRAS-Mutant Lung Cancer. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-11. Luo J, Ostrem J, Pellini B, Imbody D, Stern Y, Solanki HS, Haura EB, Villaruz LC. PMID: 35412860.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    5. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat Rev Drug Discov. 2016 11; 15(11):771-785. Ostrem JM, Shokat KM. PMID: 27469033.
      View in: PubMed   Mentions: 241     Fields:    Translation:HumansAnimalsCells
    6. A Ras-like domain in the light intermediate chain bridges the dynein motor to a cargo-binding region. Elife. 2014 Oct 01; 3:e03351. Schroeder CM, Ostrem JM, Hertz NT, Vale RD. PMID: 25272277; PMCID: PMC4359372.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansAnimalsCells
    7. OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci U S A. 2014 Jul 08; 111(27):9983-8. Chen L, Shu Y, Liang X, Chen EC, Yee SW, Zur AA, Li S, Xu L, Keshari KR, Lin MJ, Chien HC, Zhang Y, Morrissey KM, Liu J, Ostrem J, Younger NS, Kurhanewicz J, Shokat KM, Ashrafi K, Giacomini KM. PMID: 24961373; PMCID: PMC4103324.
      View in: PubMed   Mentions: 106     Fields:    Translation:AnimalsCells
    8. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013 Nov 28; 503(7477):548-51. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. PMID: 24256730; PMCID: PMC4274051.
      View in: PubMed   Mentions: 878     Fields:    Translation:HumansCells
    Jonathan's Networks
    Concepts (51)
    Derived automatically from this person's publications.
    Co-Authors (9)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department